Cardiovascular diseases are the leading cause of death in patients with diabetes mellitus. Cardiovascular diseases in diabetes mellitus are multifactorial and controlling for cardiovascular risks significantly reduces cardiovascular events. Currently, several high-quality clinical studies of novel antihyperglycemic agents, particularly sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, have been completed and proved the cardiovascular safety of these agents and found that these agents could reduce the cardiovascular outcomes, such as cardiovascular mortality, myocardial infarction, fatal and nonfatal stroke, and heart failure with reduced or preserved ejection fraction. However, at present, the clinical benefits of reducing cardiovascular risk factors or strengthening disease management (especially cardiovascular-related disease management) for diabetic patients are not particularly clear.
In this Research Topic, we hope to create a forum to discuss the clinical benefits of reducing cardiovascular risk factors and strengthening disease management for patients with prediabetes/diabetes mellitus.
We welcome submissions on the following topics, but are not limited to:
- Clinical and laboratory evidence of antihyperglycemic agents in reducing cardiovascular events in patients with diabetes mellitus
- Clinical and laboratory evidence of lipid-lowering pharmacotherapy in reducing complications in patients with diabetes mellitus
- Clinical net benefits and mechanism of blood pressure control in diabetic patients
- Role of lifestyle improvement in comprehensive cardiovascular risk management in patients with diabetes mellitus
Cardiovascular diseases are the leading cause of death in patients with diabetes mellitus. Cardiovascular diseases in diabetes mellitus are multifactorial and controlling for cardiovascular risks significantly reduces cardiovascular events. Currently, several high-quality clinical studies of novel antihyperglycemic agents, particularly sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, have been completed and proved the cardiovascular safety of these agents and found that these agents could reduce the cardiovascular outcomes, such as cardiovascular mortality, myocardial infarction, fatal and nonfatal stroke, and heart failure with reduced or preserved ejection fraction. However, at present, the clinical benefits of reducing cardiovascular risk factors or strengthening disease management (especially cardiovascular-related disease management) for diabetic patients are not particularly clear.
In this Research Topic, we hope to create a forum to discuss the clinical benefits of reducing cardiovascular risk factors and strengthening disease management for patients with prediabetes/diabetes mellitus.
We welcome submissions on the following topics, but are not limited to:
- Clinical and laboratory evidence of antihyperglycemic agents in reducing cardiovascular events in patients with diabetes mellitus
- Clinical and laboratory evidence of lipid-lowering pharmacotherapy in reducing complications in patients with diabetes mellitus
- Clinical net benefits and mechanism of blood pressure control in diabetic patients
- Role of lifestyle improvement in comprehensive cardiovascular risk management in patients with diabetes mellitus
